275 related articles for article (PubMed ID: 14736836)
1. To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT.
Antoch G; Freudenberg LS; Beyer T; Bockisch A; Debatin JF
J Nucl Med; 2004 Jan; 45 Suppl 1():56S-65S. PubMed ID: 14736836
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of gross tumor size using CT, 18F-FDG PET, integrated 18F-FDG PET/CT and pathological analysis in non-small cell lung cancer.
Yu HM; Liu YF; Hou M; Liu J; Li XN; Yu JM
Eur J Radiol; 2009 Oct; 72(1):104-13. PubMed ID: 18640802
[TBL] [Abstract][Full Text] [Related]
4. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
[TBL] [Abstract][Full Text] [Related]
5. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
[TBL] [Abstract][Full Text] [Related]
7. Acquisition protocol considerations for combined PET/CT imaging.
Beyer T; Antoch G; Müller S; Egelhof T; Freudenberg LS; Debatin J; Bockisch A
J Nucl Med; 2004 Jan; 45 Suppl 1():25S-35S. PubMed ID: 14736833
[TBL] [Abstract][Full Text] [Related]
8. Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection.
Quaia E; Tona G; Gelain F; Lubin E; Pizzolato R; Boscolo E; Bussoli L
Acta Radiol; 2008 Nov; 49(9):995-1004. PubMed ID: 18651256
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
[TBL] [Abstract][Full Text] [Related]
10. PET/CT today and tomorrow.
Townsend DW; Carney JP; Yap JT; Hall NC
J Nucl Med; 2004 Jan; 45 Suppl 1():4S-14S. PubMed ID: 14736831
[TBL] [Abstract][Full Text] [Related]
11. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G
AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
[TBL] [Abstract][Full Text] [Related]
12. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study.
Iagaru A; Mittra E; Yaghoubi SS; Dick DW; Quon A; Goris ML; Gambhir SS
J Nucl Med; 2009 Apr; 50(4):501-5. PubMed ID: 19289439
[TBL] [Abstract][Full Text] [Related]
13. Bowel hot spots at PET-CT.
Prabhakar HB; Sahani DV; Fischman AJ; Mueller PR; Blake MA
Radiographics; 2007; 27(1):145-59. PubMed ID: 17235004
[TBL] [Abstract][Full Text] [Related]
14. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
[TBL] [Abstract][Full Text] [Related]
15. PET and PET/CT in pediatric oncology.
Jadvar H; Connolly LP; Fahey FH; Shulkin BL
Semin Nucl Med; 2007 Sep; 37(5):316-31. PubMed ID: 17707239
[TBL] [Abstract][Full Text] [Related]
16. FDG-PET CT for tumor imaging.
Miller JC; Fischman AJ; Aquino SL; Blake MA; Thrall JH; Lee SI
J Am Coll Radiol; 2007 Apr; 4(4):256-9. PubMed ID: 17412280
[No Abstract] [Full Text] [Related]
17. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
18. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
[TBL] [Abstract][Full Text] [Related]
19. Diffusion-weighted imaging as part of hybrid PET/MRI protocols for whole-body cancer staging: does it benefit lesion detection?
Buchbender C; Hartung-Knemeyer V; Beiderwellen K; Heusch P; Kühl H; Lauenstein TC; Forsting M; Antoch G; Heusner TA
Eur J Radiol; 2013 May; 82(5):877-82. PubMed ID: 23428414
[TBL] [Abstract][Full Text] [Related]
20. Prosthetic vascular graft infection: the role of 18F-FDG PET/CT.
Keidar Z; Engel A; Hoffman A; Israel O; Nitecki S
J Nucl Med; 2007 Aug; 48(8):1230-6. PubMed ID: 17631553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
